Prosecution Insights
Last updated: July 17, 2026

Buckingham, Doolittle & Burroughs, LLC

5 pending office actions • 5 clients • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days

Quality Metrics (n=964 apps, methodology: how we score firms)

86.5%
Allowance Rate
n=964
+0.77σ
Allowance Rate (norm)
n=964
3.0
OAs to Allowance
n=512
-0.14σ
OAs to Allow (norm)
n=512
963 days
Time to Allowance
n=512
+7.6pp
Interview Lift
n=964
16.4%
RCE Rate
n=964
1.7%
Appeal Rate
n=964

Rejection Performance (% of received rejections ultimately overcome)

§101 Overcome
n=5 (min 20)
85.2%
§102 Overcome
n=61
88.4%
§103 Overcome
n=397
94.0%
§112 Overcome
n=50

Specialization & Scale

A61B, Y10T, A63B
Top CPC Subclasses
9%
Top-3 CPC Share
n=964
1
Practitioners
n=964
964.0
Apps / Practitioner
n=964

Portfolio Summary

5
Total Pending OAs
2
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (20%)
3
Medium (60%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (20%)
§103 only3 (60%)
§112 only1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
40% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
40% of docket
1
Business / Other
20% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SASTRI, SATYA B 1 63.1% +29.6%
CRANDALL, RICHARD W. 1 29.9% +33.8%
GEBRESILASSIE, KIBROM K 1 72.4% +25.4%
BALDORI, JOSEPH B 1 44.8% +30.1%
WESTERBERG, NISSA M 1 23.3% +36.8%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18233781 MEDIATED ANONYMOUS NEGOTIATION SYSTEM CRANDALL, RICHARD W.
18130723 SOLAR PANEL INSTALLATION DESIGN PROGRAM GEBRESILASSIE, KIBROM K
17435832 USE OF EPALRESTAT IN PREPARATION OF PANCREATIC CANCER DRUGS AND METHOD FOR VERIFYING INHIBITION EFFECT OF EPALRESTAT ON SECRETION OF EXOSOMES FROM PANCREATIC CANCER CELLS WESTERBERG, NISSA M

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18385959 ACRYLIC RANDOM COPOLYMER FOR FORMING IN SITU PEELABLE PROTECTIVE BARRIER FILMS SASTRI, SATYA B 71d overdue
17833212 SHOOTING TARGET BALDORI, JOSEPH B 15d overdue
18233781 MEDIATED ANONYMOUS NEGOTIATION SYSTEM CRANDALL, RICHARD W.
18130723 SOLAR PANEL INSTALLATION DESIGN PROGRAM GEBRESILASSIE, KIBROM K
17435832 USE OF EPALRESTAT IN PREPARATION OF PANCREATIC CANCER DRUGS AND METHOD FOR VERIFYING INHIBITION EFFECT OF EPALRESTAT ON SECRETION OF EXOSOMES FROM PANCREATIC CANCER CELLS WESTERBERG, NISSA M

Client Portfolio (5 clients)

Top Art Units

Art UnitApps
17621
36191
37111
16181

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18385959 ACRYLIC RANDOM COPOLYMER FOR FORMING IN SITU PEELABLE PROTECTIVE BARRIER FILMS Sanipeel, LLC SASTRI, SATYA B 1762 §103 Non-Final OA 71d overdue Pending Nov 01, 2023
18233781 MEDIATED ANONYMOUS NEGOTIATION SYSTEM Sunhub LLC CRANDALL, RICHARD W. 3619 §103 Final Rejection Pending Aug 14, 2023
18130723 SOLAR PANEL INSTALLATION DESIGN PROGRAM Logically Engineered Automation Features Ltd. GEBRESILASSIE, KIBROM K §101 Non-Final OA Pending Apr 04, 2023
17833212 SHOOTING TARGET Shoot Steel, Inc. BALDORI, JOSEPH B 3711 §103 Final Rejection 15d overdue Pending Jun 06, 2022
17435832 USE OF EPALRESTAT IN PREPARATION OF PANCREATIC CANCER DRUGS AND METHOD FOR VERIFYING INHIBITION EFFECT OF EPALRESTAT ON SECRETION OF EXOSOMES FROM PANCREATIC CANCER CELLS Affiliated Hospital Of Nantong University WESTERBERG, NISSA M 1618 §112 Final Rejection Pending Sep 02, 2021

Managing Buckingham, Doolittle & Burroughs, LLC's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month